Demyelination

Demyelination is a pathological process characterized by the destruction or loss of the myelin sheath, the lipid-rich insulating layer that surrounds axons in the central and peripheral nervous systems (StatPearls, 2023). This sheath is essential for saltatory conduction, which allows for the rapid and efficient transmission of electrical impulses along nerve fibers; when myelin is compromised, nerve signaling is slowed or blocked, leading to significant neurological dysfunction (National Institute of Neurological Disorders and Stroke, 2024). The etiology of demyelination is diverse, ranging from autoimmune attacks in Multiple Sclerosis (MS) to viral infections and genetic disorders like leukodystrophies. While demyelination is not a molecular target itself, it is the primary pathological focus of many therapies that aim to modulate the immune system to prevent further damage or stimulate oligodendrocyte precursor cells to achieve remyelination (PubMed, PMC7355938). Chronic demyelination is a critical driver of axonal loss, which correlates closely with permanent disability in neurodegenerative diseases.

Other names

Myelin lossDemyelinating processMyelin sheath destructionDysmyelination

Not applicable. Demyelination is a pathological condition or biological process, not a specific molecular target like a receptor or enzyme. Therapeutic agents are designed to target molecular drivers of this process (e.g., CD20, S1P receptors, or LINGO-1) to prevent myelin loss or promote its repair.